Showing results (101-110 of 160) with videos related to
Sort By:
Pageof 16
Translational Oncology|October 19, 2020
Prediction of post-radiotherapy locoregional progression in HPV-associated oropharyngeal squamous cell carcinoma using machine-learning analysis of baseline PET/CT radiomicsStefan P Haider, Kariem Sharaf, Tal Zeevi, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 21, 2024
Impact of 18F-FDG PET Intensity Normalization on Radiomic Features of Oropharyngeal Squamous Cell Carcinomas and Machine Learning-Generated BiomarkersStefan P Haider, Tal Zeevi, Kariem Sharaf, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 2, 2022
Association of TP53 and CDKN2A Mutation Profile with Tumor Mutation Burden in Head and Neck CancerAlexander Y Deneka, Yasmine Baca, Ilya G Serebriiskii, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 4, 2013
Quantification of excision repair cross-complementing group 1 and survival in p16-negative squamous cell head and neck cancersRanee Mehra, Fang Zhu, Dong-Hua Yang, et al.Annals of Surgical Oncology|August 21, 2010
Defining venous involvement in borderline resectable pancreatic cancerYun Shin Chun, Barton N Milestone, James C Watson, et al.Oral Oncology|March 28, 2024
An algorithm for standardization of tumor Infiltrating lymphocyte evaluation in head and neck cancersVasiliki Xirou, Myrto Moutafi, Yalai Bai, et al.JNCI Cancer Spectrum|January 22, 2026
STING predicts patterns of failure in locally advanced head and neck squamous cell carcinomaTyler MacNeil, Thomas J Hayman, Shengguo Li, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 17, 2019
Phase III Randomized Trial of Chemotherapy With or Without Bevacizumab in Patients With Recurrent or Metastatic Head and Neck CancerAthanassios Argiris, Shuli Li, Panayiotis Savvides, et al.Lancet (London, England)|December 5, 2018
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 studyEzra E W Cohen, Denis Soulières, Christophe Le Tourneau, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 26, 2019
Role of Treatment Deintensification in the Management of p16+ Oropharyngeal Cancer: ASCO Provisional Clinical OpinionDavid J Adelstein, Nofisat Ismaila, Jamie A Ku, et al.Pageof 16